NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair.
Código da empresaNGEN
Nome da EmpresaNervGen Pharma Corp
Data de listagemMar 13, 2019
CEORogers (Adam H)
Número de funcionários- -
Tipo de títulosOrdinary Share
Fim do ano fiscal- -
EndereçoSuite 1703 - 595 Burrard Street
CidadeVANCOUVER
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísCanada
Código postalV7X 1J1
Telefone16047225361
Sitehttps://www.nervgen.com/
Código da empresaNGEN
Data de listagemMar 13, 2019
CEORogers (Adam H)
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados